The validation of surrogate biomarkers involves rigorous clinical testing to ensure they accurately predict clinical outcomes. This process often includes retrospective studies and prospective trials to correlate biomarker levels with patient outcomes. Regulatory agencies like the FDA have specific guidelines for the validation of these biomarkers to ensure their reliability and clinical utility.
